Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders

Haematologica

Volumn 84, Issue 12, 1999, Pages 1058-1064

  Remacha, Angel F ^a   Arrizabalaga, Beatriz ^b   Villegas, Ana ^b   Manteiga, Rosa ^b   Calvo, Teresa ^b   Julià, Antoni ^b   Fernández Fuertes, Ma Isabel ^b   González, Fernando A ^b   Font, Llorenç ^b   Juncà, Jordi ^b   Del Arco, Aurora ^b   Malcorra, Juan J ^b   Equiza, Encarnación Pérez ^b   De Mendiguren, Begoña Pérez ^b   Romero, Mercedes ^b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b NONE

Author keywords

Erythropoietin; Granulocyte colony stimulating factor (G CSF); Myelodysplastic syndromes

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; COST BENEFIT ANALYSIS; FEMALE; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PATIENT COMPLIANCE; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS;

EID: 17544392895     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Sanz GF, Sanz MA, Greenberg PL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 1998; 83:358-68.
2. Bennet JM, Catovsky D, Daniel MT, et al. The French-American-British (FAB) group. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51:189-9.
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 2079-88.
4. Stenke L, Wallvik J, Celsing F, Hast R. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes. Leukemia 1993; 7:1324-7.
5. Hartung G, Weigold A, Ohl S, et al. Phase II study of subcutaneous erythropoietin for treatment of myelodysplastic syndromes. Onkologie 1995; 18:451-5.
6. Ganser A, Hoelzer D. Clinical Use of hematopoietic growth factors in the myelodysplastic syndromes. Semin Hematol 1996; 33:186-95.
7. Bowen DT, Jacobs A, Mary P, et al. Serum erythropoietin concentrations in patients with myelodysplastic syndromes. Leuk Res 1991; 15:571-5.
8. Casadevall N. Update of the role of epoetin alpha in hematologic malignancies and myelodysplastic syndromes. Semin Oncol 1998; 25(Suppl 7):12-8.
9. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995; 89:67-71.
10. Hansen PB, Penkowa M, Johnsen HE. Hematopoietic growth factors for the treatment of myelodysplastic syndromes. Leuk Lymphoma 1998; 28:491-500.
11. Cazzola M, Mercuriali F, Brugnara C. Review: Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997; 89:4248-68.
12. Hellström-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997; 99:344-51.
13. Spivak JL. The biology and clinical applications of recombinant erythropoietin. Semin Oncol 1998; 25 (Suppl7):7-11.
14. Mittelman M, Gardyn J, Carmel M, Malovani H, Barak Y, Nir U. Analysis of the erythropoietin receptor gene in patients with myeloproliferative and myelodysplastic syndromes. Leuk Res 1996; 20:459-66.
15. Souza LM, Boone TC, Gabrilove J, et al. Recombinant human granulocyte colony-stimulating factor: effect on normal and leukemic myeloid cells. Science 1986; 232:61-7.
16. Remacha AF, Martino R, Sureda A, et al. Changes in reticulocyte fractions during peripheral stem cell harvesting: role in monitoring stem cells collection. Bone Marrow Transplant 1996; 17:163-8.
17. Italian cooperative study group for rHuEpo in myelodysplastic syndromes. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 1998; 103:1070-4.
18. Cazzola M, Anderson JE, Ganser A, Hellström-Lindberg E. A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica 1998; 83: 910-35.
19. Hellström-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998; 92:68-75.
20. Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy. Blood 1996; 87:4076-81.
21. Hoefsloot LH, Van Amelsvoort MP, Broeders LCAM, et al. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndromes. Blood 1997; 89:1690-700.
22. Aoki A, Shibata A. In vitro study of erythropoiesis in patients with aplastic anemia and myelodysplastic syndromes: A possible tool for prospective determination of the clinical effectiveness of growth factors. Hematol Pathol 1992; 6:143-53.
23. Asano H, Ohashi H, Ichihara M, et al. Evidence for nonclonal hematopoietic progenitor cell populations in bone marrow of patients with myelodysplastic syndromes. Blood 1994; 84:588-94.